N4P

N4 Pharma

N4 Pharma updates on Nuvec AAV Viral Vector research

N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments, gene therapy and vaccines, has provided a further successful update on its ongoing research

N4 Pharma

N4 Pharma plc Nuvec Oral Delivery Update

N4 Pharma Plc (LON: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided a positive update on its ongoing oral delivery research

N4 Pharma

N4 Pharma plc Nuvec® R&D and Strategy Update

N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an encouraging update on its ongoing in vitro siRNA research work. The

N4 Pharma

N4 Pharma launch Interactive Investor Hub

N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced the launch of the N4 Pharma Interactive Investor Hub.

STRIX GROUP PLC ORD 1P
Strix Group plc CEO Mark Bartlett discusses the company's focus on safety controls, global reach, innovation, and growth opportunities for investors.
Firering Strategic MineralS PLC
Learn about Firering Strategic Minerals plc's operations and future plans from an exclusive interview with their Independent Non-Executive Director, Vassilios Carellas.
Pulsar Helium Inc
Discover insights into the helium sector as Stephane Foucard delves into the projects of junior companies, assessing key criteria for commercial viability.
Golden Matrix Group Inc
Golden Matrix Group Inc. CEO Brian Goodman discusses revenue growth, acquisitions, and global markets in an exclusive interview with DirectorsTalk.
XP Factory plc
XP Factory plc's CEO discusses financial highlights, growth targets, and a £10 million credit facility with Barclays in an exclusive interview with DirectorsTalk.